Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3 Mln
P/E Ratio
--
P/B Ratio
0.36
Industry P/E
--
Debt to Equity
--
ROE
-1.21 %
ROCE
-194.62 %
Div. Yield
0 %
Book Value
1840.93
EPS
-1792.49
CFO
$-36.11 Mln
EBITDA
$-0.94 Mln
Net Profit
$11.02 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Quoin Pharmaceuticals (QNRX)
| -73.17 | -41.81 | -70.39 | -73.55 | -95.48 | -89.91 | -- |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Quoin Pharmaceuticals (QNRX)
| -86.51 | -71.21 | -93.76 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.79 | 9,808.03 | 20.22 | 23.13 | |
| 289.41 | 8,956.09 | 22.08 | 58.42 | |
| 26.79 | 9,559.25 | -- | -28.77 | |
| 103.51 | 10,030.35 | 30.81 | 14.16 |
Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical... lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc. Address: 42127 Pleasant Forest Court, Ashburn, VA, United States, 20148-7349 Read more
Co-Founder, CEO & Chairman
Dr. Michael Myers Ph.D.
Co-Founder, CEO & Chairman
Dr. Michael Myers Ph.D.
Headquarters
Ashburn, VA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Quoin Pharmaceuticals Ltd (QNRX) stood at $ 15,709 Mln as on 31-Dec-24
The share price of Quoin Pharmaceuticals Ltd (QNRX) is $6.11 (NASDAQ) as of 23-Apr-2025 13:36 EDT. Quoin Pharmaceuticals Ltd (QNRX) has given a return of -95.48% in the last 3 years.
Quoin Pharmaceuticals Ltd (QNRX) has a market capitalisation of $ 3 Mln as on 22-Apr-2025. As per Value Research classification, it is a company.
Since, TTM earnings of Quoin Pharmaceuticals Ltd (QNRX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Quoin Pharmaceuticals Ltd (QNRX) and enter the required number of quantities and click on buy to purchase the shares of Quoin Pharmaceuticals Ltd (QNRX).
Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc. Address: 42127 Pleasant Forest Court, Ashburn, VA, United States, 20148-7349
The CEO & director of Dr. Michael Myers Ph.D.. is Quoin Pharmaceuticals Ltd (QNRX), and CFO & Sr. VP is Dr. Michael Myers Ph.D..
There is no promoter pledging in Quoin Pharmaceuticals Ltd (QNRX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Quoin Pharmaceuticals Ltd. (QNRX) | Ratios |
|---|---|
|
Return on equity(%)
|
-194.62
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Quoin Pharmaceuticals Ltd (QNRX) was $0 Mln.
$0.11
(
